CNN’s sperm-count report highlights why fertility goals belong in TRT discussions and why a single semen result needs clinical context.
On October 13, 2026, CNN published a report by urologist Dr. Jamin Brahmbhatt comparing sperm-count research and explaining why fertility plans belong in discussions about testosterone treatment.
This article is for informational purposes only and is not medical advice. Personal decisions about testing, fertility and hormone treatment belong with a qualified clinician.
CNN’s report describes two analyses with different findings. The useful starting point is to understand what each reported rather than reduce the debate to a simple claim that sperm counts are either falling everywhere or staying unchanged.
According to CNN, a 2022 global meta-analysis included 223 studies and more than 57,000 men across 53 countries. It estimated that average sperm concentration fell 51.6% and total sperm count fell 62.3% between 1973 and 2018. Those are the analysis’s estimates across its study population and time period.
CNN also describes a 2025 review of 58 studies involving 11,787 American men without known infertility. In its initial analysis of samples collected from 1970 through 2018, the review found no overall change in sperm concentration. After adjustment for geographic region and fertility status, it found a modest annual decline.
That change after adjustment is part of the result rather than an optional footnote. An accurate account needs both the initial finding and the adjusted finding. Quoting only one would change the meaning of the review as CNN presents it.
The headline debate is therefore about more than choosing between opposing conclusions. It also concerns which men were studied and how the information was analysed. CNN uses that debate to draw attention to reproductive health without presenting the findings as a countdown to fatherhood.
The report’s most direct treatment-related point concerns exogenous testosterone, meaning testosterone supplied from outside the body. CNN says it can suppress sperm production and sometimes reduce it to zero. That makes fertility a relevant part of a discussion about testosterone replacement therapy, commonly called TRT.
Brahmbhatt’s reported advice is clear: CNN says he tells men who want children now or in the future to avoid TRT. This is advice attributed to the urologist who wrote the report. It places parenthood plans at the beginning of the conversation rather than treating them as a concern to address after therapy starts.
CNN also advises men concerned about low-testosterone symptoms to ask a doctor about options that preserve fertility. The central point is not that a reader should select a different medicine from an article. It is that the clinician needs to know whether having children is part of the person’s current or future plans.
A discussion focused only on possible low-testosterone symptoms would leave that priority unaddressed. The questions are related but distinct: what is causing the concern, and how do fertility goals affect the options under consideration? The report supports bringing both questions into the same clinical assessment.
This shifts the practical emphasis away from the population debate. A man does not need to settle whether worldwide sperm counts are declining before raising his own parenthood plans. The reported effect of testosterone therapy on sperm production is the more immediate issue for that treatment conversation.
CNN’s article is a news report discussing existing research and clinical advice. It is not a newly published treatment trial or a new clinical guideline. Its findings need to be read within that scope.
The global analysis and the American review did not examine the same populations. The latter focused on American men without known infertility and its conclusion changed after statistical adjustment. These differences limit any attempt to turn the findings into one universal statement about every population.
The two analyses should therefore retain their separate descriptions. The global estimates should not be assigned to an individual man. Likewise, the initial American finding should not be used to erase the adjusted result or dismiss the broader research.
CNN explains that semen measures vary. Neither sperm concentration nor one abnormal semen analysis should be treated as a definitive verdict on an individual man’s fertility.
The report also says semen abnormalities can prompt a review of health and medications. However, it explicitly cautions that an abnormal result alone does not diagnose heart disease or diabetes. It does not establish a prediction of early death either.
For follow-up testing, CNN reports that the American Urological Association recommends at least two semen analyses. It says these should ideally be about a month apart, especially when the first result may be abnormal. This is reported guidance for clinical assessment rather than a testing schedule for readers to arrange independently.
CNN does not name specific fertility-preserving alternatives. Its advice to ask about such options should not be read as evidence that one universal substitute for TRT is suitable for everyone with possible low-testosterone symptoms.
The report also does not establish that testosterone-related suppression is permanent or identical in every man. Treatment selection requires assessment of the underlying condition and fertility goals. It is not something to resolve by matching a symptom to a medicine mentioned elsewhere online.
For readers weighing similar claims, Testostra’s guide to assessing hormone and sexual-health evidence provides additional educational context.
The report’s practical value is a clearer discussion before a treatment decision. Fertility plans should be stated explicitly when asking a clinician about possible low-testosterone symptoms. CNN includes both wanting children now and wanting them in the future in its account of Brahmbhatt’s advice.
A useful consultation can address the symptom concern and the reproductive goal together. The conversation does not have to begin with a request for TRT or a particular alternative. It can begin with the concern that prompted the appointment and the importance of preserving fertility.
For someone whose plans are uncertain, that uncertainty is still relevant to mention. There is a difference between having no immediate plans for children and deciding that future parenthood is not a consideration. The clinician should not have to infer that distinction from the fact that testosterone treatment has been raised.
Questions grounded in CNN’s report include:
These questions seek an assessment rather than a prescription from a news story. They also keep the focus on the person’s priorities instead of assuming that a higher testosterone result is the only outcome that matters.
If a semen result prompted the concern, the discussion can address what follow-up is appropriate. If possible low-testosterone symptoms prompted it, the discussion can address how those symptoms should be assessed. Neither route requires the reader to decide on a treatment before speaking with a clinician.
CNN’s reported repeat-testing guidance gives that conversation a concrete starting point when an initial semen analysis may be abnormal. The clinician can explain how the guidance applies to the situation and what the next result would contribute to the assessment.
For broader education, Testostra’s discussion of testosterone results in clinical context addresses questions around changing hormone levels. Its resource on shared TRT decisions also covers the treatment conversation without replacing individual care.
CNN’s report offers another practical direction: semen abnormalities can be a reason to review health and medications with a clinician. That makes the result a starting point for questions rather than a label attached to the whole person.
A fertility-focused appointment can therefore include asking whether a wider review is appropriate. The purpose is to understand the concern in context. It is not to draw conclusions about unrelated diseases from a reproductive test.
CNN’s report does not justify changing medical practice solely because of sperm-count headlines. It reinforces a specific clinical priority: fertility goals belong in the assessment before testosterone therapy is considered. The next step supported by the report is a qualified discussion about symptoms and parenthood plans, with testing and treatment options considered in that context.
Sperm-count headlines raise a decision about seeking care rather than choosing a hormone treatment; Testostra supplies clear context on the research behind that distinction. Its coverage addresses uncertainty over possible low-testosterone symptoms and their causes through explanations of testing and TRT evidence, with individual medical decisions left to qualified clinicians.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra